There is no single best weight-loss medication; the right one depends on your health history, other medicines, tolerability and cost. For scale, in trials semaglutide 2.4 mg averaged 14.9% weight loss at 68 weeks (STEP 1, NEJM 2021) and tirzepatide 15 mg averaged 20.9% at 72 weeks (SURMOUNT-1, NEJM 2022). Those are trial results, not REMEVi averages.
That may sound like a dodge. It isn’t. It is how obesity medicine actually works, and understanding why will help you have a more useful conversation with your provider. Here is what the FDA-approved options are, what their trials reported, how pills and injections differ, what they cost, and how a clinician narrows them down with you.
Recommendations and results for approved medicines depend on the indication and product. NIDDK describes weight-management medication as part of a plan that also includes nutrition, activity and follow-up. Source: NIDDK: prescription weight-management medicines
Is there a single best weight-loss medication?
Quick answer: No. The FDA has approved several options that work differently, and the right one depends on your health history, other medicines, tolerability, access and cost.
The U.S. Food and Drug Administration has approved six medications for long-term chronic weight management, according to the NIDDK’s list, and approved a further oral option, Foundayo (orforglipron), on April 1, 2026. They don’t all work the same way, they don’t all suit the same people, and none of them carries a “best in class” label. The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) is direct about this: choosing a medication to treat overweight or obesity is a decision between you and your health care professional. FDA: Foundayo approval
The reason is that the right medication depends on the person. A drug that is an obvious fit for one patient can be a poor choice for the next because of a thyroid history, a seizure disorder, an interaction with an antidepressant, a pregnancy plan, or simply what their insurance will cover. A medication only helps if you can actually take it safely and stay on it, and that is a personal calculation, not a universal one.
So the useful question isn’t “what is the best weight-loss medication?” It’s “which FDA-approved option is the right fit for my body, my health history, and my life?” That reframing is the whole point of this article.
Which weight-loss medications are FDA-approved?
Quick answer: Semaglutide (Wegovy), tirzepatide (Zepbound), liraglutide (Saxenda), phentermine-topiramate (Qsymia), naltrexone-bupropion (Contrave), orlistat (Xenical, alli) and, since April 2026, orforglipron (Foundayo).
According to the NIDDK, the FDA has approved six medications for long-term use in chronic weight management. Wegovy is now available as a weekly injection and as a daily tablet, and Foundayo was approved in April 2026. Here is what each is and how it works, stated plainly and without ranking them.
| Medicine (brand) | How it is taken | How it works |
|---|
| Semaglutide (Wegovy) | Weekly injection or daily tablet | Mimics GLP-1, a hormone that acts on brain areas regulating appetite and food intake |
| Tirzepatide (Zepbound) | Weekly injection | Mimics two hormones, GIP and GLP-1 |
| Liraglutide (Saxenda) | Daily injection | Mimics GLP-1 |
| Orforglipron (Foundayo) | Daily tablet, with or without food | An oral GLP-1 receptor agonist |
| Phentermine-topiramate (Qsymia) | Once-daily pill | Combines an appetite suppressant with a medicine also used for seizures and migraine |
| Naltrexone-bupropion (Contrave) | Oral pill | Acts on pathways involved in appetite and food reward |
| Orlistat (Xenical; lower-dose alli) | Oral, linked to meals | Reduces how much dietary fat your gut absorbs |
Sources: NIDDK medication overview, Wegovy prescribing information, Foundayo prescribing information.
Semaglutide (Wegovy) mimics a hormone called GLP-1, which acts on areas of the brain that regulate appetite and food intake. Under different names and doses, semaglutide is also FDA-approved to treat type 2 diabetes as an injection (Ozempic) and as an oral tablet (Rybelsus).
Tirzepatide (Zepbound) is a weekly injection that mimics two hormones, GIP and GLP-1, to target the same appetite-regulating pathways. Under a different name, tirzepatide is FDA-approved to treat type 2 diabetes (Mounjaro).
Liraglutide (Saxenda) is a daily injection that also mimics GLP-1. At a lower dose under the name Victoza, it is approved to treat type 2 diabetes.
Phentermine-topiramate (Qsymia) is a once-daily pill that combines an appetite suppressant with a medication also used for seizures and migraine; it may make you feel less hungry or full sooner.
Naltrexone-bupropion (Contrave) is an oral pill that pairs a medication used for alcohol and drug dependence with one used for depression and smoking cessation, and may reduce appetite.
Orlistat (Xenical, and lower-dose Alli) is an oral medication that works in your gut to reduce how much fat your body absorbs from food.
The NIDDK also lists setmelanotide (IMCIVREE) for a small number of people with specific rare genetic disorders confirmed by testing, and notes that some appetite suppressants such as phentermine on its own are FDA-approved only for a few weeks rather than long-term use. Off-label prescribing exists too, and you should feel comfortable asking your clinician whether a medication is being used on- or off-label.
Several of the newer options work by mimicking GLP-1, a hormone your gut releases that signals fullness to your brain. Semaglutide targets the GLP-1 receptor; tirzepatide targets both GLP-1 and a second receptor, GIP. The mechanism is the same idea in different molecular forms.
Notice what this list does and doesn’t tell you. It tells you the mechanism and the format. It doesn’t tell you which is “best,” because that isn’t a property of the drug. It is a property of the match between the drug and the person.
How much weight did people lose in the trials?
Quick answer: In trials, semaglutide 2.4 mg averaged 14.9% at 68 weeks (STEP 1) and tirzepatide 15 mg 20.9% at 72 weeks (SURMOUNT-1). Trial results, not REMEVi averages.
These figures come from each product’s own trial, with its own population, dose and length. They are group averages for brand medicines, not a personal forecast and not results for compounded preparations.
| Medicine and trial dose | Trial | Average weight change in the trial | Placebo |
|---|
| Semaglutide 2.4 mg weekly injection (Wegovy) | STEP 1, NEJM 2021, 68 weeks | −14.9% | −2.4% |
| Tirzepatide 15 mg weekly injection (Zepbound) | SURMOUNT-1, NEJM 2022, 72 weeks | −20.9% | −3.1% |
| Oral semaglutide 25 mg daily (Wegovy tablets) | OASIS 4, 64 weeks | −13.6% | −2.2% |
| Orforglipron, highest approved dose (Foundayo) | Foundayo label, Table 6, 72 weeks | −11.1% | −2.1% |
| Liraglutide, phentermine-topiramate, naltrexone-bupropion, orlistat | Each product’s own label | Not quoted here; ask your clinician to walk through the label | — |
Comparing percentages across separate trials does not establish that one medicine works better than another: the designs, populations and handling of missing data differ. One direct comparison exists for the two weekly injections. In the open-label SURMOUNT-5 trial (NEJM 2025), adults with obesity without type 2 diabetes averaged 20.2% weight loss on tirzepatide and 13.7% on semaglutide at 72 weeks, at the maximum tolerated trial doses. That trial was funded by Eli Lilly and did not test compounded preparations.
Should I choose a weight-loss pill or an injection?
Quick answer: Neither format is automatically better. The exact medicine, its daily routine, how you tolerate it and your health history matter more than whether it is swallowed or injected.
One of the first forks in the decision is format. Some of these medications are injections and some are pills, and people often have a strong instinct one way or the other. Injectables like the GLP-1 medications are once-weekly or daily shots; oral options are taken by mouth, sometimes more than once a day.
| Question | Injections (Wegovy, Zepbound, Saxenda) | Pills (Wegovy tablets, Foundayo, Qsymia, Contrave, orlistat) |
|---|
| How often | Weekly (Wegovy, Zepbound) or daily (Saxenda) | Daily; orlistat is linked to meals |
| Daily routine | An injection on a schedule, with training for the pen or device | Varies by product: Wegovy tablets are taken in the morning on an empty stomach with up to four ounces of water, then at least 30 minutes before food, drinks or other oral medicines; Foundayo may be taken with or without food |
| Mechanism | GLP-1 or GIP/GLP-1 receptor agonists | Two are oral GLP-1 options; the others use fat absorption or other appetite-related pathways |
| Dose conversion | Milligrams do not convert between products or routes | Do not convert oral and injectable doses yourself |
Sources: Wegovy label, section 2.1, Foundayo label, section 2, NIDDK.
The right one depends on the same factors as everything else here: your health profile, how each option is tolerated, and what fits your life. We break down the real trade-offs in our guide to weight-loss pills versus injections, which is worth reading if the format question is where you’re stuck.
How much do weight-loss medications cost per 4 weeks?
Quick answer: It depends on the product, dose, insurance and manufacturer program. Some self-pay offers are published; insurance can change the price entirely.
Cost and access are part of the clinical decision, so it helps to know what you might pay before the appointment. Manufacturer self-pay offers change, and an introductory price is not always the ongoing price.
| Option | What the manufacturer advertises (checked September 14, 2026) | What changes the price |
|---|
| Wegovy pens, 0.25 through 2.4 mg | $349 per box of four pens, ongoing, after any applicable introductory offer; the 7.2 mg HD pen and tablets are priced separately | Formulation, dose, eligibility and insurance. Source |
| Zepbound | A starting price of $299 for a four-week supply of 2.5 mg, a starting dose rather than maintenance | Dose, device and refill terms. Source |
| Other FDA-approved options | Not quoted here | Pharmacy, plan formulary, prior authorization and deductible |
| REMEVi compounded GLP-1 programs | See current REMEVi pricing | Plan length and preparation; prices use four-week periods |
These are manufacturer offers subject to eligibility and changeable terms, not a price promise for every prescription. If you have coverage, see does insurance cover GLP-1 medications; for the full brand breakdowns, read how much Wegovy costs and how much Zepbound costs.
How does a clinician choose a weight-loss medication with you?
Quick answer: By weighing likely benefits, possible side effects, your other conditions and medicines, your family history and cost, as the NIDDK describes, then matching those to each option.
This is the part that matters most. The NIDDK lays out the factors a clinician weighs when choosing a weight-management medication with you, and they are worth knowing before your appointment:
- The likely benefits of weight loss for your health. Not a number, but whether losing weight is likely to improve specific conditions you have.
- The medication’s possible side effects. Every option has them, and some rule out certain patients entirely, such as a personal or family history of medullary thyroid cancer for the GLP-1 medications.
- Your current health issues and other medications. Interactions and existing conditions narrow the list fast. Contraindications like glaucoma, seizure history, or certain antidepressants matter here.
- Your family’s medical history.
- Cost and access, including what your insurance will and won’t cover.
A clinician takes those inputs and matches them against the mechanism and safety profile of each option. That is why two people who weigh the same and want the same result can walk out with two different prescriptions, or with a recommendation to start with lifestyle changes and no medication at all. The NIDDK is clear that these medications are meant to be combined with a lifestyle program of healthier eating and more physical activity, not as a replacement for it.
If you want to compare two of the most-discussed options head to head, our semaglutide vs tirzepatide breakdown walks through how those two specifically differ.
How soon will you know if a medication is working?
Quick answer: The NIDDK guidance is to reassess if you haven’t lost at least 5% of your starting weight after 12 weeks on the full dose.
There is a built-in checkpoint. If you haven’t lost at least 5% of your starting weight after 12 weeks on the full dose, the NIDDK guidance is to reassess, adjust, or switch, rather than stay on something that isn’t working. Choosing a medication is the start of a managed process, not a one-time pick.
How does REMEVi decide which medication to prescribe?
Quick answer: A licensed clinician reviews your health history and decides whether a prescription is appropriate and, if so, which option fits your profile.
At REMEVi, the “which medication is right for me” question isn’t something you answer alone from a search result. A licensed clinician reviews your health history and works with you to decide whether a prescription is appropriate and, if so, which one fits your profile. That is the whole model: clinician-led care, not a vending machine.
What we can promise on the practical side is transparency. Our pricing is published, with no insurance call required to find out what you’d pay, and care coaching is built in rather than sold as an add-on. If a compounded GLP-1 is part of your plan, you’ll know exactly what it is. Compounded semaglutide and tirzepatide are non-FDA-approved preparations made by a state-licensed U.S. compounding pharmacy under an individual prescription; they are not a generic version of, and are not the same as, Ozempic, Wegovy, Mounjaro, or Zepbound. The trial figures above describe brand medicines, not compounded preparations. GLP-1 medications are FDA-approved for specific indications, and eligibility is determined by a clinician.
You can see how the process works and what’s included on our prescription weight-loss page, or start with a look at how it works.
What should you bring to the appointment?
Quick answer: Your full health history, a complete medicine and supplement list, pregnancy plans, insurance details and what you can afford over time.
Finding the right medication is a clinical decision built on your health history, your other conditions and medications, the side-effect profile of each option, and cost. The FDA-approved options each work differently, and the match between a medication and a person is what makes one appropriate and another not. The most useful move isn’t picking a winner off a list. It’s bringing your full history to a clinician who can help you choose safely.
If you’re ready to have that conversation, you can talk to a licensed clinician at remevihealth.com.
This article is for informational purposes only and is not medical advice. It does not recommend any specific medication. Weight-management medications are prescription-only and must be evaluated and prescribed by a licensed provider. Compounded semaglutide and tirzepatide are non-FDA-approved preparations. They are not a generic version of, and are not the same as, Ozempic®, Wegovy®, Mounjaro®, or Zepbound®. Compounded preparations have not been clinically studied as finished products. Consult a licensed provider before starting any prescription medication.
